Medical Disorders
Resources
Basic InformationLookupsLatest News
Drop in Life Expectancy From COVID Much Worse for Black, Hispanic AmericansInnovative Kidney Donor 'Voucher' System Is Saving LivesMental Confusion an Early Warning Sign of Severe COVID-19COVID Caused Biggest Drop in U.S. Life Expectancy Since World War IIClot-Removing Procedure Can Sometimes Backfire for Stroke PatientsFDA to Add Warning to Pfizer, Moderna Vaccines About Rare Heart Issues in YoungAHA News: Silent Heart Attacks All Too Common, and Often OverlookedRash, Itch After COVID Vaccine Rare & Quickly ResolvesStudy Suggests COVID Vaccine Booster Shots Will Be NeededNo Need for Blood Thinners in Patients Sick at Home With COVID-19Heart Issues in Young COVID Vaccine Recipients Rare, Usually Mild and Quickly Resolve: ExpertsMore E-Scooter Rideshares, More InjuriesMore Than Half of People With Asthma Aren't Seeing a SpecialistAutopsy Study Shows How COVID Harms the BrainCOVID Deaths Drop to New Lows in U.S., While Vaccination Rates ClimbNot-So-Happy-Birthdays: Parties Helped Spread COVID, Study FindsAHA News: Should Rare Cases of Heart Inflammation Put Your COVID-19 Vaccine Plans on Hold?Obesity in Teens Raises Adult Diabetes Risk, Even After Weight LossNew Genetic Insights Into Cause of ALSScreen All Kids for Heart Problems, Pediatricians' Group SaysIn 11 States, Seniors' Low Vaccination Rates a 'Powder Keg' for New CasesSickle Cell Plagues Many Black Americans, But There's Hope for Better TreatmentsSurvivors' Plasma Helps Blood Cancer Patients Battle COVID-19Hospitals: One Reason COVID Is More Lethal for Black AmericansMany 'High Priority' Patients Aren't Getting Put on Kidney Transplant ListsU.S. to Spend $3.2 Billion to Help Develop Antiviral Pills for COVIDRed Cross Warns of Severe Blood ShortageHand Sanitizer Vapors Can Cause Nausea, DizzinessPfizer, Moderna Vaccines Do No Harm to Male Fertility: StudyLess Than 1% of People Who've Had Severe COVID Get Re-InfectedMold a Big Threat to People With COPDWhat Works Best to Ease Migraines?Pandemic Silver Lining: Fewer Dangerous Flare-Ups for COPD PatientsIs Zinc a Friend or Foe to Kidney Stones?Strict Rest Not Recommended After Sports-Linked Concussion, Experts SayEven Good Weather Didn't Lift Lockdown Blues: StudyU.S. ​COVID Death Toll Tops 600,000Third Dose of COVID Vaccine Boosts Protection in Transplant RecipientsCould a Type of Statin Raise Dementia Risks?Many U.S. Seniors May Need Better Knee Arthritis CareAfter COVID, Many Americans Are Struck by New Maladies: StudyCataracts: Common, and Easy to TreatThere Are Many Good Reasons for Kids to Get the COVID VaccineBabies Produce Strong Immune Response to Ward Off COVID-19: StudyNovavax's COVID Vaccine Shines in Latest TrialAHA News: U.S. Appears to Lose Ground in Controlling High Blood PressureWeight-Loss Surgeries Used Least in U.S. States That Need Them MostObesity Could Raise Odds for 'Long-Haul' COVID SymptomsSmokers, Obese People Need Major Heart Interventions Earlier in LifeOld Age No Bar to Successful Heart Transplant, Study Finds
Questions and AnswersVideosLinksBook Reviews
Related Topics

Cancer
Men's Health
Women's Health

Many Existing Drugs Could Be Potent COVID Fighters: Study

HealthDay News
by Robert Preidt
Updated: Jun 7th 2021

new article illustration

MONDAY, June 7, 2021 (HealthDay News) -- It has been an elusive goal so far -- finding a potent treatment that can beat back the new coronavirus before it grabs a hold of a patient's immune system and sends it into overdrive.

But new research suggests that more than a dozen existing drugs or drugs under development may do the trick.

Investigators tested more than 12,000 drugs in two different types of human cells infected with SARS-CoV-2. The drugs were either approved by the U.S. Food and Drug Administration or had been tested for safety in humans.

From those thousands of drugs, the researchers identified 90 that prevented SARS-CoV-2 from replicating in at least one of the human cell lines.

Of those drugs, 19 were found to work in concert with or boost the activity of remdesivir, an antiviral therapy already approved for treatment of COVID-19.

"Some of the most effective antiviral strategies are 'cocktails' in which patients are given several different drugs to combat the infection, such as those used to treat HIV infections," said study author Dr. Thomas Rogers, an adjunct assistant professor in the Department of Immunology and Microbiology at Scripps Research Institute in La Jolla, Calif.

Of the 19 drugs that showed promise, 13 demonstrated the highest potential to be used as oral COVID-19 therapies, based on factors such as potency, likely mechanism of action and safety, the researchers said.

Four of the 13 drugs -- halofantrine, nelfinavir, simeprevir and manidipine -- are already FDA-approved and the nine others are in various stages of development, according to the study published June 3 in the journal Nature Communications.

Two additional drugs heightened remdesivir's ability to suppress the virus, the study found: These two drugs were riboprine, a compound that's been tested as a preventative for nausea and surgical infection, and 10-deazaaminopterin, a derivative of the vitamin folic acid.

"While we now have effective vaccines against COVID-19, we still lack highly effective antiviral drugs that can prevent COVID-19 infections or stop them from worsening," said Peter Schultz, president and CEO of Scripps Research.

"Our results raise the possibility of a number of promising avenues for repurposing existing oral medications with efficacy against SARS-CoV-2," he said in a Scripps news release. "It is critical we proceed with the utmost rigor to determine what is safe and effective, as diligence is the most expedient path to finding new therapies that will make a difference for patients."

More information

The U.S. Centers for Disease Control and Prevention has more on COVID-19 treatment.

SOURCE: Scripps Research Institute, news release, June 3, 2021




Facebook

Amazon Smile

 

Children and Adult services are available now with no wait time.  

Please contact HBH at 860-548-0101, option 2.

 


powered by centersite dot net